Iontophoretic Delivery of Subretinal Progenitor Stem Cells and Gene Therapies for RP

Research into treating RP using iontophoretic delivery of subretinal progenitor stem cells and gene therapies is quite intriguing. Retinitis pigmentosa is a group of inherited disorders characterized by progressive vision loss due to the degeneration of photoreceptor cells in the retina.
Using iontophoresis, a technique that employs an electric current to enhance the delivery of therapeutic agents across biological barriers, such as the retina, holds promise for targeted and efficient delivery of stem cells and gene therapies. Subretinal progenitor stem cells can potentially differentiate into various retinal cell types, replacing damaged or lost cells in the retina. Gene therapies aim to correct genetic mutations underlying RP or provide neuroprotective effects to slow down disease progression.
Combining these approaches could offer a multifaceted treatment strategy for RP, addressing both the underlying genetic defects and the degenerative changes in the retina. However, further preclinical and clinical studies are needed to assess the safety, efficacy, and long-term outcomes of iontophoretic delivery of these therapies in RP patients. Additionally, optimizing the delivery parameters, such as current intensity and duration, is crucial to maximize therapeutic benefits while minimizing adverse effects.
Contact us for any question about restore vision:
[e-mail]

[@user-rz4ki5ht6o]

Does this reverse glaucoma dead cell